See the DrugPatentWatch profile for cosentyx

There is limited information available on the direct interaction between Cosentyx (secukinumab) and the MMR (measles, mumps, and rubella) vaccine. However, it is important to note that Cosentyx is an immunosuppressive drug, which can potentially affect the efficacy of vaccines [1].

Secukinumab, the active ingredient in Cosentyx, is a monoclonal antibody that selectively binds to interleukin-17A, a naturally occurring cytokine in the body, and inhibits its interaction with the IL-17 receptor [2]. This inhibition can influence the immune response, which is crucial for the effectiveness of vaccines [1].

The Centers for Disease Control and Prevention (CDC) recommends that individuals on immunosuppressive therapy, like Cosentyx, should consult their healthcare provider regarding the need for additional doses of certain vaccines or the timing of vaccination [3]. This is because immunosuppressive drugs can potentially lead to an attenuated response to vaccines [1].

In summary, while there is no specific information on Cosentyx affecting MMR vaccine potency, immunosuppressive drugs like Cosentyx can potentially impact vaccine efficacy. Therefore, it is recommended to consult a healthcare provider before receiving vaccinations while on Cosentyx [1][3].

Sources:
[1] https://www.ncbi.nlm.nih.gov/books/NBK221752/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125557s000lbl.pdf
[3] https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer-biontech.html#vaccination-of-person-receiving-immunosuppressive-therapies